Analyst Ratings For NASDAQ:ALDR – Alder Biopharmaceuticals (NASDAQ:ALDR)
Today, Mizuho reiterated its Buy rating on NASDAQ:ALDR – Alder Biopharmaceuticals (NASDAQ:ALDR) with a price target of $29.00.
Some recent analyst ratings include
- 6/7/2018-Mizuho Reiterated Rating of Buy.
- 5/9/2018-Needham & Company LLC Reiterated Rating of Buy.
- 4/24/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- 3/4/2018-Leerink Swann Reiterated Rating of Outperform.
- On 6/1/2018 Jeffrey T L Smith, Director, sold 12,161 with an average share price of $17.85 per share and the total transaction amounting to $217,073.85.
- On 6/1/2018 Mark James Litton, Insider, sold 22,727 with an average share price of $17.84 per share and the total transaction amounting to $405,449.68.
- On 5/16/2018 Jeffrey T L Smith, Insider, sold 12,161 with an average share price of $15.03 per share and the total transaction amounting to $182,779.83.
- On 11/13/2017 Mark James Litton, Insider, sold 16,519 with an average share price of $10.80 per share and the total transaction amounting to $178,405.20.
- On 10/16/2017 Mark James Litton, Insider, sold 16,520 with an average share price of $12.33 per share and the total transaction amounting to $203,691.60.
- On 7/18/2017 Stephen M Dow, Director, bought 25,000 with an average share price of $10.00 per share and the total transaction amounting to $250,000.00.
- On 6/20/2017 Jeffrey T L Smith, VP, sold 585 with an average share price of $20.00 per share and the total transaction amounting to $11,700.00.
Recent Trading Activity for NASDAQ:ALDR – Alder Biopharmaceuticals (NASDAQ:ALDR)
Shares of NASDAQ:ALDR – Alder Biopharmaceuticals closed the previous trading session at 17.40 down -0.75 4.13% with 18.25 shares trading hands.